Anti-CD19 CAR NK therapy (Xinqiao Hospital)

N/A

Report date: 2022/09/06 18:04:06

Base Information

Drug NameAnti-CD19 CAR NK therapy (Xinqiao Hospital)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacements

TargetsNot applicable

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesThe Second Affiliated Hospital of Army Medical University

China Registration ClassN/A

Develop Information

Active CompaniesThe Second Affiliated Hospital of Army Medical University

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeN/A